Mumps Vaccine | Market Size, Share & Growth Report 2025-2033
The Mumps Vaccine Market Report is Segmented by Product Type (Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines, and Others), Application (Hospitals, Clinics, and Others), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), Ingredient Type (Mumps Virus).
Mumps Vaccine Market
Market Analysis
How the market stands today, and what is shaping it
The global mumps vaccine market was estimated at approximately USD 1.85 billion in 2025 and is projected to reach around USD 2.78 billion by 2033, representing a CAGR of approximately 5.20% during 2025–2033, based on Core Market Research estimates. Mumps antigen is supplied almost entirely within combination vaccines: the trivalent measles, mumps and rubella products M-M-R II and PRIORIX, and the tetravalent ProQuad adding varicella, all using live attenuated virus. Growth is supported by delivery through national childhood immunisation schedules that renew with each birth cohort, by a third-dose recommendation for at-risk groups during outbreaks, and by higher demand in Asia Pacific and Europe. Expansion is constrained by waning vaccine-induced immunity, by recurring stockouts in measles-containing vaccines, and by the widespread use of measles-rubella vaccine that omits mumps antigen entirely. Competition operates in separate price tiers rather than head to head, with interchangeability formally established between the two products serving the highest-value market. The leading franchise declined 3% across the first nine months of 2025.
Market Dynamics
Key market dynamics and their impact on the industry landscape
Market Drivers
- Mumps immunisation is delivered through national childhood schedules rather than by prescription, so demand renews with each birth cohort automatically. Programme inclusion rather than clinical decision determines volume, which makes the base unusually stable compared with therapeutic markets.
- ACIP recommended a third mumps-containing dose for people at increased risk during an outbreak, following its October 2017 meeting. Outbreak response creates episodic demand above the scheduled two doses, in a population already counted as fully vaccinated.
- The FDA approved PRIORIX on 6 June 2022 and ACIP recommended it on 23 June 2022 as fully interchangeable with the incumbent product. A second approved supplier reduces the risk that a single manufacturing interruption halts national supply.
- United States federal contract prices of USD 26.345 and USD 26.33 per dose, against private sector prices near USD 98 and USD 95, show a purchasing structure that funds childhood immunisation publicly while private demand is billed far higher. Both channels are reimbursed rather than paid out of pocket.
- Higher demand in Asia Pacific and Europe, with favourable European tender timing, partly offset a 3% decline in the leading supplier's combined franchise across the first nine months of 2025. Growth outside the United States is absorbing part of the decline within it.
Market Challenges
- The stored figures for this report were previously USD 35.8 billion for 2025 falling to USD 2.9 billion by 2029. That size exceeded the entire global vaccine market for all products by a wide margin and has been recalculated to USD 1.85 billion against published references and disclosed supplier revenue.
- The leading franchise is contracting. Combined sales of ProQuad, M-M-R II and Varivax fell 3% to USD 592 million across the first nine months of 2025, on lower United States demand and unfavourable timing of CDC purchases, and that franchise also includes a varicella product beyond this market.
- Vaccine-induced immunity to mumps wanes. A third dose temporarily raises antibody titres but they return close to baseline after about a year, so the intervention available for outbreaks provides short-term rather than durable protection.
- It has been suggested that people vaccinated with the Jeryl Lynn strain may not hold protective titres against currently circulating wild-type strains, because of differences in antigenic epitopes. The dominant strain in high-income markets faces an open question about its match to circulating genotypes.
- Measles-containing vaccines were among the products with the most stockouts recorded in the WHO market assessment, with procurement and funding delays cited. Supply interruption in this category recurs rather than occurring exceptionally.
Opportunities
- A mumps antigen that is not egg-based and attenuated could allow reformulation away from the manufacturing constraints of current products. No inactivated or recombinant mumps vaccine is licensed, so the two supplied product categories that are empty represent an open technical gap.
- A strain matched more closely to circulating genotypes could address the suggestion that Jeryl Lynn-derived immunity may not protect against current wild-type virus, which is the strongest clinical argument for a new product in a market otherwise served adequately.
- Durable outbreak protection would be commercially distinct from the current third dose, whose effect returns close to baseline within about a year. A product providing lasting boost would convert episodic outbreak demand into a defined adult indication.
- A second approved supplier in the United States since 2022 may allow competitive tendering in a market that had none for 44 years, which could expand programme volume where price had constrained it.
- Countries currently using measles-rubella vaccine could switch to the trivalent product, which would add mumps coverage to programmes that presently omit it. That is the largest identified route to volume growth, though it depends on national programme decisions rather than commercial action.
Trends and Insights
Key market trends shaping the industry landscape
Value and Volume Sit in Different Regions
High impactLong-termUnited States private sector prices near USD 98 per dose contrast with international tender awards between USD 0.90 and USD 1.50.
Insight: A roughly hundredfold price spread means dose share and revenue share describe almost opposite geographies, so any regional analysis must state which of the two it is measuring.
Single Supply Has Ended in the Largest Market
Medium impactMid-termA second measles, mumps and rubella vaccine was approved in the United States in June 2022, after 44 years in which one product served the entire national requirement.
Insight: Interchangeability was granted immediately, so the second entrant competes on price and supply reliability rather than on clinical difference, which is unusual for a vaccine launch.
Waning Immunity Creates Recurring Outbreaks
High impactMid-termOutbreaks rose substantially from late 2015 among previously vaccinated populations, prompting a third-dose recommendation for at-risk groups during outbreaks.
Insight: Demand is no longer bounded by the birth cohort, because fully vaccinated adults become a periodically addressable population, though only during declared outbreaks.
Manufacturing Has Shifted to Emerging Producers
Medium impactLong-termOne Indian manufacturer accounts for roughly 80% of global measles-rubella supply and is one of two WHO-prequalified producers.
Insight: Global supply security now depends on a very small number of producers, which is consistent with measles-containing vaccines being among the most stockout-prone products recorded.
Measles-Rubella Displaces Mumps Coverage
High impactLong-termMuch of the highest-volume programme supply is measles-rubella vaccine, which contains no mumps antigen.
Insight: Large parts of the world receive measles and rubella protection without mumps, so this market is structurally confined to countries that have chosen the trivalent product.
Segment Analysis
Market segmentation by product type, application, distribution channel, ingredient type
Live Attenuated Vaccines account for the entire market in practice. Mumps immunisation uses weakened virus strains, principally Jeryl Lynn in the products sold in high-income markets and Hoshino and other strains in vaccines produced for emerging markets, and the attenuated approach is what generates the durable cellular response the schedule depends on. Inactivated Vaccines and Recombinant Vaccines are listed but no licensed mumps product uses either approach, so two of the four supplied values have no product behind them. That absence is commercially significant rather than incidental: an inactivated or recombinant mumps antigen would allow reformulation away from the egg-based attenuated manufacturing that constrains supply, and no such product exists. Others covers the tetravalent presentation combining the three antigens with varicella, which is a format difference rather than a different technology.
Geography Analysis
Regional market analysis
North America
North America holds the largest share of market value and much the smallest share of doses, and the gap between those two facts defines the region. CDC price list figures put M-M-R II at USD 26.345 per dose on federal contract and USD 97.990 in the private sector, with PRIORIX at USD 26.33 and USD 95.201 and the tetravalent ProQuad at USD 186.55 and USD 289.168. Those prices are roughly twenty to one hundred times what international tenders pay, so a modest dose volume converts into a large revenue pool. The regional ranking rests on that documented price and commercial concentration rather than on a measured regional market size. No regional market size or growth figure from a source usable in this report was identified for any region. The region is also where supply changed most, ending 44 years of single supply in 2022.
Europe
Europe buys through national tender rather than at private-market prices, which places it between the North American and emerging-market tiers on value per dose. Tender timing rather than underlying demand drives the reported quarter-to-quarter pattern. Favourable European tender timing was cited as one factor partly offsetting a 3% decline in the leading supplier's combined franchise across the first nine months of 2025, alongside genuinely higher demand in the region. PRIORIX was licensed across European countries well before it reached the United States, so the region has had two suppliers for far longer and has not experienced the single-supply position North America held until 2022. No European market size or growth figure usable in this report was identified.
Asia Pacific
Asia Pacific is named the fastest-growing region here on the strength of demand rather than of a measured market rate. The leading supplier identified higher demand in Asia Pacific, alongside Europe, as partly offsetting lower United States demand across the first nine months of 2025, which is the only directional regional evidence found. No regional market growth figure usable in this report was identified for any region, so this ranking is a documented judgement rather than a measurement. The region also holds the largest manufacturing base for measles-containing vaccines: one Indian manufacturer shipped approximately 236 million doses of measles-rubella vaccine in 2022, around 80% of global MR supply, and is one of only two WHO-prequalified producers, with 81 member states using its product. Its mumps-containing product uses the Hoshino strain rather than Jeryl Lynn.
Latin America
Latin America procures largely through the PAHO revolving fund and national programmes, which places it firmly in the low-price tier where value per dose is a small fraction of North American levels. Measles-containing vaccines were among the products with the highest number of stockouts recorded in the WHO market assessment, with procurement and funding delays cited, and regions dependent on pooled procurement are the most exposed to that failure mode. No market size, revenue or growth figure usable in this report was identified for the region. The structural position is that high coverage combined with low unit price produces substantial volume and modest revenue, so the region matters more to disease control than to the market's value.
Middle East & Africa
This region takes the largest share of doses at the lowest prices and therefore the smallest share of value of the five. Supply reaches it predominantly through UNICEF tender from emerging-market manufacturers, where award prices for measles, mumps and rubella vaccine have been recorded between USD 0.90 and USD 1.50 per dose, against a United States private-sector price near USD 98. Much of the region also uses measles-rubella vaccine rather than the trivalent product, which contains no mumps antigen at all and therefore falls outside this market despite serving the same programme. No market size or growth figure usable in this report was identified. Where measles-rubella is the programme product, mumps is effectively not vaccinated against.
Competitive Landscape
Key players and market positioning analysis
This market has very few suppliers, and they operate in effectively separate price tiers rather than competing directly with one another. Merck & Co., Inc. holds the incumbent position in the United States with M-M-R II, which was the only measles, mumps and rubella vaccine available there from 1978 until 2022, and with ProQuad, the tetravalent presentation adding varicella. Its combined ProQuad, M-M-R II and Varivax sales fell 3% to USD 592 million across the first nine months of 2025, on lower United States demand and unfavourable timing of CDC purchases, partly offset by higher demand in Asia Pacific and Europe. GSK plc broke that single supply with PRIORIX, approved by the FDA on 6 June 2022 for people aged 12 months and older. ACIP recommended it unanimously on 23 June 2022 as safe, immunogenic and non-inferior, and fully interchangeable with the incumbent for all recommended uses. PRIORIX was already licensed in more than 100 countries with over 800 million doses distributed, so its United States approval extended an established product rather than launching a new one. Serum Institute of India Pvt. Ltd. supplies the emerging-market tier, shipping approximately 236 million doses of measles-rubella vaccine in 2022, roughly 80% of global supply, as one of only two WHO-prequalified producers, with 81 member states using its product. Its trivalent product uses the Hoshino mumps strain rather than Jeryl Lynn. Three participants are listed because the market genuinely contains few: mumps antigen is produced by a small number of manufacturers worldwide. The principal competitive factors are supply reliability, price tier and national programme inclusion rather than clinical differentiation, since interchangeability has been formally established between the two products competing in the highest-value market.
Major Players
Leading companies in the market
Industry Developments
5 recorded developments
Combined sales of ProQuad, M-M-R II and Varivax declined 3% to USD 592 million across the first nine months of 2025, on lower United States demand and unfavourable timing of CDC purchases. Higher demand in Asia Pacific and Europe, with favourable European tender timing, partly offset the fall.
Measles-containing vaccines were among the products with the highest number of stockouts recorded in the WHO global vaccine market assessment, with procurement and funding delays given as the causes. Supply interruption in this category is a recurring rather than exceptional event.
The FDA approved PRIORIX on 6 June 2022 for prevention of measles, mumps and rubella in people aged 12 months and older, ending 44 years of single supply. ACIP unanimously recommended it on 23 June 2022 as fully interchangeable with the incumbent.
Following its October 2017 meeting, ACIP recommended a third dose of a mumps virus-containing vaccine for people previously given two doses who are identified as being at increased risk during an outbreak. The recommendation responded to a substantial rise in United States outbreaks since late 2015.
M-M-R II became the only measles, mumps and rubella vaccine available in the United States from 1978, a position it held without challenge for more than four decades. A single supplier carried the entire national requirement for three diseases.
Table of Contents
13 comprehensive chapters
1.1 Market Definition
1.2 Scope of the Study
1.3 Research Objectives
2.1 Research Approach
2.2 Data Sources
2.3 Market Estimation Approach
2.4 Forecast Assumptions
2.5 Research Limitations
3.1 Market Overview
3.2 Market Size and Forecast
3.3 Key Findings
3.4 Market Structure
4.1 Market Drivers
4.2 Market Challenges
4.3 Market Opportunities
4.4 Market Trends and Insights
5.1 Market Segmentation Overview
5.2 By Product Type
5.3 By Application
5.4 By Distribution Channel
5.5 By Ingredient Type
6.1 North America
6.2 Europe
6.3 Asia Pacific
6.4 Latin America
6.5 Middle East & Africa
6.6 Regional Market Comparison
7.1 Industry Developments
7.2 Industry Timeline
8.1 Market Structure and Competitive Positioning
8.2 Major Players
8.3 Strategic Developments
8.4 Key Competitive Factors
9.1 Merck & Co., Inc.
9.2 GSK plc
9.3 Serum Institute of India Pvt. Ltd.
10.1 Market Size and Growth Outlook
10.2 Regional Market Outlook
10.3 Future Market Trends
10.4 Key Risks to the Forecast
11.1 Growth Opportunities
11.2 Key Risks and Constraints
11.3 Strategic Considerations
13.1 Glossary of Terms
13.2 Abbreviations
13.3 Research References
Scope of the Report
Report coverage and methodology
Study Period
Base Year: 2025
Forecast Period: 2025 - 2033
Geographic Scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Covered
Merck & Co., Inc., GSK plc, Serum Institute of India Pvt. Ltd. + more
Data Sources
Primary research, industry interviews, regulatory filings, company reports
Frequently Asked Questions
Common questions about this report
Ready to Get the Full Report?
Access comprehensive market insights, detailed analysis, and strategic recommendations to make informed business decisions.